|
| Section2 = | Section3 = }} GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.〔Sten Stovall, "(Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria )," The Wall Street Journal, August 4, 2010〕〔Melly Alazraki, "(GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' )" Daily Finance, August 6, 2010〕〔 (primary source)〕 No animal studies have been reported. No application has been made for human clinical trials. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「GSK 299423」の詳細全文を読む スポンサード リンク
|